— Results Provide Support for Advancing SYN-005 into Clinic —
ROCKVILLE, Md., April 27, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.
Pertussis is a highly contagious disease caused by the bacteria Bordetella pertussis (B. pertussis) with symptoms that include severe coughing and subsequent breathing difficulties. Antibiotic use does not have a major effect on the disease course because, while it can eliminate the B. pertussis bacteria from the respiratory tract, it does not neutralize pertussis toxin. This secreted toxin is a major cause of disease virulence as it paralyzes the immune system, causes the white blood cell count to increase (sometimes to levels that block blood flow through the lungs), and predisposes infants to severe pneumonia.
Pertussis can be fatal in infants; therefore, attacking pertussis toxin in infants is an urgent unmet medical need. According to the World Health Organization, there are approximately 50 million worldwide cases of whooping cough each year, leading to an estimated 300,000 deaths, primarily among young, unvaccinated infants. Synthetic Biologics is developing SYN-005 through its Exclusive Channel Collaboration with Intrexon Corporation (NYSE: XON) and academic researchers at The University of Texas at Austin to target and neutralize the pertussis toxin in order to reduce morbidity and mortality in infected infants.
The “Antibody Cocktail Effectively Treats Pertussis in a Baboon Disease Model” poster summarized preclinical efficacy data that support advancing Synthetic Biologics’ novel monoclonal antibody combination (hu1B7 and hu11E6), SYN-005, toward the clinic. The poster presented key data from both murine and non-human primate models with the following conclusions:
- In the murine model, prophylactic administration of hu1B7 and hu11E6, both individually and in combination, completely blocked the rise in white blood cell count that is characteristic of the disease and reduced bacterial colonization in the lungs.
- In the non-human primate model, therapeutic administration of SYN-005 reversed the rise in white blood cell count and accelerated the clearance of pertussis bacteria.
The second poster, entitled “Spontaneous Identification of Bordetella bronchiseptica in a Baboon Colony: Potential Ramifications for Bordetella pertussis Modeling” presented data that further evaluated 16 non-human primates and provided new information important to the future use of this model.
“The data suggest that SYN-005 has therapeutic potential to diminish morbidity, long-term complications and mortality from Pertussis in critically ill infants,” said Jennifer Maynard, Ph.D., Associate Professor at The University of Texas at Austin’s McKetta Department of Chemical Engineering. “In addition, the data support a prophylactic approach for use in newborns that has the potential to save thousands of lives annually, particularly in the developing world where the unmet need is greatest.”
“Presenting at the ECCMID meeting allowed us to highlight both the therapeutic and prophylactic potential of SYN-005,” stated Mike Kaleko, M.D., Ph.D., Senior Vice President, Research and Development for Synthetic Biologics. “This research provides a strong body of evidence as Synthetic Biologics seeks non-dilutive funding to support advancing SYN-005 to the clinic.”
In September 2014, the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the Company’s proprietary SYN-005 monoclonal antibody combination for the treatment of Pertussis.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapeutics focused on protecting the microbiome, as well as treating other diseases. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C), and in collaboration with Intrexon Corporation (NYSE: XON), a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the therapeutic potential of SYN-005 to diminish morbidity, long-term complications and mortality from Pertussis in critically ill infants, the potential for SYN-005 to save thousands of lives annually, particularly in the developing world where the unmet need is greatest and the size of the potential market. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, the additional clinical studies and results not meeting expectations, the inability to raise non-dilutive funding, the inability to commence and complete clinical trials when expected and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2014 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/posters-at-eccmid-2015-highlight-preclinical-data-from-synthetic-biologics-novel-syn-005-monoclonal-antibody-combination-for-the-treatment-and-prophylaxis-of-whooping-cough-pertussis-300072176.html
SOURCE Synthetic Biologics, Inc.
Released April 27, 2015